Peter Kellogg
Directeur Financier/CFO chez RECEPTOS INC
Fortune : 21 647 $ au 30/04/2024
Profil
Peter N.
Kellogg is currently serving as an Independent Director at Alnylam Pharmaceuticals, Inc. and as a Director at Juno Therapeutics, Inc. He is also a Non-Executive Director at Idorsia Ltd.
and a Director at Idorsia Pharmaceuticals Ltd.
Additionally, he holds the position of Chief Financial Officer & Executive Vice President at Receptos LLC.
In his former roles, Mr. Kellogg served as an Independent Director at Yield10 Bioscience, Inc. from 2007 to 2020.
He was also the Chief Financial Officer & Executive Vice President at Biogen MA, Inc. from 2000 to 2003, and at Merck & Co., Inc. from 2007 to 2014.
Furthermore, he held the position of Senior Vice President-eCommerce at PepsiCo, Inc. in 2000, and Chief Financial Officer & Executive Vice President at Schering-Plough Corp.
in 2009.
He also served as the Chief Financial Officer & Executive Vice President at Biogen, Inc. from 2003 to 2007.
Mr. Kellogg's education includes an undergraduate degree from Princeton University in 1978 and an MBA from The Wharton School of the University of Pennsylvania in 1982.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IDORSIA LTD.
0,01% | 31/12/2022 | 10 969 ( 0,01% ) | 21 647 $ | 30/04/2024 |
| 31/01/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Peter Kellogg
| Sociétés | Poste | Début |
|---|---|---|
| RECEPTOS INC | Directeur Financier/CFO | - |
| JUNO THERAPEUTICS INC | Directeur/Membre du Conseil | - |
| IDORSIA LTD | Directeur/Membre du Conseil | 12/05/2021 |
| ALNYLAM PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 07/03/2023 |
Idorsia Pharmaceuticals Ltd.
 Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Directeur/Membre du Conseil | - |
Anciens postes connus de Peter Kellogg
| Sociétés | Poste | Fin |
|---|---|---|
| YIELD10 BIOSCIENCE, INC. | Directeur/Membre du Conseil | 11/02/2020 |
| CELGENE | Directeur Financier/CFO | 01/08/2018 |
| MERCK & CO., INC. | Directeur Financier/CFO | 23/04/2014 |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Directeur Financier/CFO | 03/11/2009 |
| ░░░░░ ░░░░░ ░░░░░ ░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Peter Kellogg
| Princeton University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| YIELD10 BIOSCIENCE, INC. | Process Industries |
| MERCK & CO., INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| PEPSICO, INC. | Consumer Non-Durables |
| IDORSIA LTD | Health Technology |
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 13 |
|---|---|
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | Finance |
PepsiCo Food International
 PepsiCo Food International Beverages: Non-AlcoholicConsumer Non-Durables Part of PepsiCo, Inc., PepsiCo Food International is a carbonated beverage company. The company is based in Purchase, NY. | Consumer Non-Durables |
| Frito-Lay International | |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Merck Sharp & Dohme Corp.
 Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. | Health Technology |
Pepsi-Cola International Ltd. (New York)
 Pepsi-Cola International Ltd. (New York) Beverages: Non-AlcoholicConsumer Non-Durables Part of PepsiCo, Inc., Pepsi-Cola International Ltd. is a company based in Purchase, NY. The company makes soft drinks and snack foods. | Consumer Non-Durables |
Pepsi-Cola North America
 Pepsi-Cola North America Beverages: Non-AlcoholicConsumer Non-Durables Pepsi-Cola North America manufactures and markets beverage products. It offers soft drinks, bottled waters, iced teas, juices, and sports drinks. The company is headquartered in Purchase, NY | Consumer Non-Durables |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Health Technology |
